Mark Christopher Capone's most recent trade in Mesa Laboratories, Inc. was a trade of 1,404 Restricted Stock Units - 2 done . Disclosure was reported to the exchange on Aug. 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mesa Laboratories, Inc. | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 1,404 | 1,404 | - | - | Restricted Stock Units - 2 | |
| Mesa Laboratories, Inc. | Mark Christopher Capone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 724 | 724 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories, Inc. | Mark Christopher Capone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 724 | 0 | - | - | Restricted Stock Units - 1 | |
| Mesa Laboratories, Inc. | Mark Capone Christopher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 724 | 724 | - | - | Restricted Stock Units -1 | |
| DermTech Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 35,714 | 82,054 (0%) | 0% | 0 | Common Stock | |
| DermTech Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 26,480 | 26,480 (0%) | 0% | 0 | Common Stock | |
| DermTech Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 19,860 | 46,340 (0%) | 0% | 0 | Common Stock |